anti mouse gr1 antibody (ATCC)
Structured Review

Anti Mouse Gr1 Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1253 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+ll+2/LL%2F2/pmc13090963-69-11-9
Average 99 stars, based on 1253 article reviews
Images
1) Product Images from "Circulating low-density neutrophils as biomarkers of resistance to first-line anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer"
Article Title: Circulating low-density neutrophils as biomarkers of resistance to first-line anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer
Journal: Translational Oncology
doi: 10.1016/j.tranon.2026.102755
Figure Legend Snippet: Tumor growth kinetics following anti–PD-1, chemotherapy, and anti-Gr1 treatment in LLC tumor–bearing mice. (A): Diagram representing the therapeutic scheme followed for the in vivo experiment. LLC cells were injected subcutaneously on day 0 to establish tumours. Treatments were administered intraperitoneally on days 11, 14, and 17 after tumor cell inoculation, with anti-GR1 administered one day prior to each treatment cycle. The therapeutic regimens included anti-PD1 (100 μg/mouse), anti-GR1 (200 μg/mouse), and chemotherapy consisting of cisplatin (3 mg/kg) plus pemetrexed (100 mg/kg). (B): Growth curves of LLC cells subcutaneously injected into immunocompetent mice, comparing tumour volumes between control and (B) anti-PD-1 treatment, (C) anti-Gr1 treatment, (D) chemotherapy consisting on cisplatin plus pemetrexed, plus anti-PD-1 treatment, (E) chemotherapy plus anti-PD-1 plus anti-Gr1 treatment. *: p <0.05; ***: p <0.001; ****: p <0.0001.
Techniques Used: In Vivo, Injection, Control
Related Articles
Modification:Article Title: Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Article Snippet: Human DU-145 cell line (ATCC no. HTB-81; obtained in 2014) was grown in Eagle’s minimum essential medium (Merck) with the same supplementation as mentioned above. .. Article Title: Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms Article Snippet: Human DU-145 cell line (ATCC no. HTB-81; obtained in 2014) was grown in Eagle’s minimum essential medium (Merck) with the same supplementation as mentioned above. .. other:Article Title: Multi-targeted therapy resistance via drug-induced secretome fucosylation Article Snippet: Article Title: Widespread multi-targeted therapy resistance via drug-induced secretome fucosylation Article Snippet: Article Title: Multi-targeted therapy resistance via drug-induced secretome fucosylation Article Snippet: Cell Culture:Article Title: SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via Transcriptional and Posttranslational Regulation of β-Catenin in Lung Cancer Article Snippet: .. The human cell lines (A549, LTEP-a-2 and HEK293), mouse B16-F10 cell line (High lung metastatic model) and Incubation:Article Title: SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via Transcriptional and Posttranslational Regulation of β-Catenin in Lung Cancer Article Snippet: .. The human cell lines (A549, LTEP-a-2 and HEK293), mouse B16-F10 cell line (High lung metastatic model) and |
